The importance of the optimal dose of acetylsalicylic acid in prevention of cardiovascular events Review article
Article Sidebar
Published:
Jun 30, 2023
Keywords:
acetylsalicylic acid, cardiovascular prevention, secondary prevention, chronic coronary syndromes, myocardial infarction, stroke, peripheral artery disease
Main Article Content
Abstract
Acetylsalicylic acid is the most commonly used antiplatelet drug. Acetylsalicylic acid plays a key role in the treatment and prevention of cardiovascular events, i.e.: acute coronary syndromes, chronic coronary syndromes, stroke, peripheral arterial disease, as well as in primary prevention in patients with diabetes and at least high risk. In chronic treatment, acetylsalicylic acid is usually used in the so-called low dose – 75–100 mg, and the selection of the appropriate dose may be influenced by the individual profile of the patient, taking into account, e.g. high patient weight, presence of diabetes and the risk of ischemic and hemorrhagic events.
Article Details
How to Cite
Ozierański, K., & Kapłon-Cieślicka, A. (2023). The importance of the optimal dose of acetylsalicylic acid in prevention of cardiovascular events. Medycyna Faktow (J EBM), 16(2(59), 147-150. https://doi.org/10.24292/01.MF.0223.03
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007; 109(6): 2285-92.
2. Tymińska A. Kwas acetylosalicylowy w świetle aktualnych zaleceń. Świat Medycyny i Farmacji. 30 Sierpnia 2022.
3. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-60.
4. Szymański F, Filipiak K, Krasiński Z et al. Jaką dawkę kwasu acetylosalicylowego należy stosować w codziennej praktyce klinicznej? Wielodyscyplinarne stanowisko ekspertów. Choroby Serca i Naczyń. 2016; 13(3): 147-58.
5. Pawliczak F, Kasprzak JD. Kwas acetylosalicylowy AD 2019 – znane zalety, nowe wyzwania. Folia Cardiologica. 2019; 14(5): 467-74.
6. Rothwell PM, Cook NR, Gaziano JM et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018; 392(10145): 387-99.
7. Theken KN, Grosser T. Weight-adjusted aspirin for cardiovascular prevention. Lancet. 2018; 392(10145): 361-2.
8. Collet JP, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289-367.
9. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52(7): e364-e467.
10. Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407-77.
11. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119-77.
12. Aboyans V, Ricco JB, Bartelink MEL et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763-816.
13. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
14. World Health Organization. WHO model list of essential medicines – 22nd list 2021 (access: 5.05.2023).
15. Mourikis P, Zako S, Dannenberg L et al. Aspirin antiplatelet effects are associated with body weight. Vascul Pharmacol. 2020; 125-126: 106635.
16. Rosiak M, Postuła M, Kapłon-Cieślicka A et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiol Pol. 2013; 71(6): 552-7.
17. Rosiak M, Postula M, Kaplon-Cieslicka A et al. Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study. Cardiol J. 2013; 20(5): 545-51.
18. Duzenli MA, Ozdemir K, Aygul N et al. Comparison of Increased Aspirin Dose Versus Combined Aspirin Plus Clopidogrel Therapy in Patients With Diabetes Mellitus and Coronary Heart Disease and Impaired Antiplatelet Response to Low-Dose Aspirin. Am J Cardiol. 2008; 102(4): 396-400.
2. Tymińska A. Kwas acetylosalicylowy w świetle aktualnych zaleceń. Świat Medycyny i Farmacji. 30 Sierpnia 2022.
3. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-60.
4. Szymański F, Filipiak K, Krasiński Z et al. Jaką dawkę kwasu acetylosalicylowego należy stosować w codziennej praktyce klinicznej? Wielodyscyplinarne stanowisko ekspertów. Choroby Serca i Naczyń. 2016; 13(3): 147-58.
5. Pawliczak F, Kasprzak JD. Kwas acetylosalicylowy AD 2019 – znane zalety, nowe wyzwania. Folia Cardiologica. 2019; 14(5): 467-74.
6. Rothwell PM, Cook NR, Gaziano JM et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018; 392(10145): 387-99.
7. Theken KN, Grosser T. Weight-adjusted aspirin for cardiovascular prevention. Lancet. 2018; 392(10145): 361-2.
8. Collet JP, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289-367.
9. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52(7): e364-e467.
10. Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407-77.
11. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119-77.
12. Aboyans V, Ricco JB, Bartelink MEL et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763-816.
13. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
14. World Health Organization. WHO model list of essential medicines – 22nd list 2021 (access: 5.05.2023).
15. Mourikis P, Zako S, Dannenberg L et al. Aspirin antiplatelet effects are associated with body weight. Vascul Pharmacol. 2020; 125-126: 106635.
16. Rosiak M, Postuła M, Kapłon-Cieślicka A et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiol Pol. 2013; 71(6): 552-7.
17. Rosiak M, Postula M, Kaplon-Cieslicka A et al. Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study. Cardiol J. 2013; 20(5): 545-51.
18. Duzenli MA, Ozdemir K, Aygul N et al. Comparison of Increased Aspirin Dose Versus Combined Aspirin Plus Clopidogrel Therapy in Patients With Diabetes Mellitus and Coronary Heart Disease and Impaired Antiplatelet Response to Low-Dose Aspirin. Am J Cardiol. 2008; 102(4): 396-400.